GNPX - Genprex in-licenses additional gene therapy technologies for treatment of lung cancer

Genprex ([[GNPX]] +2.5%) announces that it has in-licensed additional gene therapy technologies for the treatment of lung cancer.The company and a major cancer research center in Houston, Texas has entered into an amendment to their May 2020 License Agreement enabling the exclusive license.Genprex has been granted exclusive worldwide license to an additional portfolio of six patents and one patent application and related technology.Newly licensed technologies include use of Genprex’s TUSC2 gene therapy combined with EGFR inhibitors or other anti-cancer therapies in patients predicted to be responsive to TUSC2 therapy.An Institutional Review Board ("IRB") had granted approval for Genprex's phase 1/2 trial testing its REQORSA immunogene therapy with AstraZeneca’s Tagrisso (osimertinib) in late-stage non-small cell lung cancer, on Wednesday.

For further details see:

Genprex in-licenses additional gene therapy technologies for treatment of lung cancer